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Background:  Prostacyclin receptor (IP receptor) agonists, which are used in the treatment of pulmonary arterial hypertension (PAH), 
increase cytosolic cAMP levels and thereby cause pulmonary vasodilation and inhibition of smooth muscle cell proliferation. Tachyphylaxis 
following repeated exposure to agonists may occur via receptor desensitization/internalization. This study analyzed β-arrestin recruitment 
- a measure of receptor uncoupling - and IP receptor internalization in response to ACT-333679, the active metabolite of the experimental 
PAH drug selexipag.
methods:  Recombinant IP receptor expressing CHO cells were used to characterize the prostacyclin analogs iloprost, beraprost, 
treprostinil and the non-prostanoid IP receptor agonist ACT-333679 with respect to their potency and efficacy to activate adenylate 
cyclase, to recruit β-arrestin, and to internalize IP receptors. We employed cAMP accumulation assays, β-arrestin enzyme fragment 
complementation assays, immunofluorescence microscopy, and flow cytometry.
results:  In cAMP accumulation assays, all four compounds acted as full agonists (Emax ~ 100%) with EC50 values between 0.1 and 
1.1 nM. In β-arrestin recruitment assays intrinsic EC50 values were between 35 and 212 nM. The non-prostanoid agonist ACT-333679 
displayed lower maximal efficacy in recruiting β-arrestin (Emax=40%) compared to the prostacyclin analogues iloprost, beraprost and 
treprostinil (Emax= 100, 90 and 67%, respectively). Lower β-arrestin recruitment efficacy translated into a lack of IP receptor internalization 
in ACT-333679-treated cells, even at high agonist concentrations. In contrast, iloprost, beraprost and treprostinil induced strong receptor 
internalization, as shown by immunofluorescence microscopy and flow cytometry.
conclusion:  ACT-333679, the active metabolite of selexipag, while retaining full efficacy in inducing cAMP responses, does not lead to 
IP receptor desensitization and internalization like the classical prostacyclin analogs and might therefore not result in tachyphylaxis upon 
multiple dosing in vivo.
